source
- WuXi AppTec lifts 2026 revenue outlook despite US defense designation disputeWuXi AppTec, a leading Chinese contract research and manufacturing organization, announced it has again lifted its revenue forecast for 2026. The company said the upward revision reflects accelera…
- J&J's Halda-derived prostate cancer drug shows 75% response in early Phase 1 trialJohnson & Johnson's recent $3 billion purchase of Halda Therapeutics added an oral prostate cancer candidate, JNJ-6143, to its pipeline. The drug targets a cancer-specific protein to trigger cell d…